Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study

• Published in: International journal of colorectal disease Vol. 29; no. 3; pp. 387 - 393
• Main Authors: Krokowicz, Lukasz, Stojcev, Zoran, Kaczmarek, Bartosz Filip, Kociemba, Wojciech, Kaczmarek, Elżbieta, Walkowiak, Jaroslaw, Krokowicz, Piotr, Drews, Michal, Banasiewicz, Tomasz
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2014; Springer; Springer Nature B.V
• Subjects: Analysis; Butyric Acid - administration & dosage; Butyric Acid - therapeutic use; Capsules; Colonoscopy; Diverticulitis; Diverticulitis, Colonic - prevention & control; Diverticulosis; Diverticulosis, Colonic - complications; Diverticulosis, Colonic - drug therapy; Double-Blind Method; Esters; Female; Gastroenterology; Hepatology; Histamine Antagonists - administration & dosage; Histamine Antagonists - therapeutic use; Humans; Internal Medicine; Male; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Middle Aged; Original; Original Article; Proctology; Prospective Studies; Quality of Life; Surgery; Prevention; Sodium butyrate; Diverticulosis; Diverticulitis
• ISSN: 0179-1958; 1432-1262; 1432-1262
• DOI: 10.1007/s00384-013-1807-5

Background Microencapsulated sodium butyrate (MSB) has been previously associated with anti-inflammatory and regenerative properties regarding large bowel mucosa. We aimed to examine a role of MSB in patients with diverticulosis, hypothesizing its potential for reduction of diverticulitis episodes and diverticulitis prevention. Methods Seventy-three patients with diverticulosis (diagnosed in colonoscopy or/and barium enema or/and CT colography) were recruited for the study and randomized. The investigated group was administered MSB 300 mg daily; the control group was administered placebo. After 12 months, a total of 52 patients completed the study and were subject to analysis (30 subjects and 22 controls). During the study, the number of episodes of diverticulitis (symptomatic diagnosis with acute pain, fever, and leukocytosis), hospitalizations, and surgery performed for diverticulitis were recorded. Additionally, a question regarding subjective improvement of symptoms reflected changes in quality of life during the analysis. Results After 12 months, the study group noted a significantly decreased number of diverticulitis episodes in comparison to the control group. The subjective quality of life in the study group was higher than in the control group. There were no side effects of the MSB during the therapy. Conclusions MSB reduces the frequency of diverticulitis episodes, is safe, and improves the quality of life. It can play a role in the prevention of diverticulitis.